GLP-1 coaching claims on TikTok: what holds up?

What did @taylorreidcoachin actually say?

About four to five weeks into using retatrutide, the creator added "one milligram of congruent" to her regimen and reported that by the next day she had "no food noise" and "no appetite." She framed this as an immediate, dramatic suppression of hunger signals after starting a second peptide alongside an ongoing retatrutide protocol.

A few things worth flagging right away: she appears to be stacking two peptides simultaneously, and the dosing she describes, one milligram introduced without any apparent ramp-up context, is not a clinically established starting point for any approved or investigational GLP-1 class agent. The term "congruent" is not a recognized pharmaceutical name, which makes it difficult to assess exactly what compound she was using.

Does the science back this up?

Rapid appetite suppression after starting a GLP-1 receptor agonist is a real, documented phenomenon, but the overnight timeline she describes is faster than what clinical pharmacology would predict for most of these agents.

Retatrutide is a triple agonist (GLP-1, GIP, glucagon receptors) currently in Phase 2/3 trials. Jastreboff et al. (2023, NEJM) showed significant weight loss and appetite reduction in participants over 24 weeks, but the onset of appetite effects in that trial was gradual, not overnight. GLP-1 receptor agonists do reduce gastric emptying and hypothalamic hunger signaling, which can feel acute to some users, but individual variation is enormous. Some people notice appetite changes within days; others take weeks. Attributing a sudden change specifically to a dose increase of a second unnamed compound is impossible to verify scientifically.

What did they get wrong (or right)?

She is not wrong that GLP-1 class peptides reduce food noise and appetite. That is one of the most consistently reported effects across clinical trials and patient experience data. Jastreboff et al. (2022, NEJM) on tirzepatide and Wilding et al. (2021, NEJM) on semaglutide both document significant appetite suppression as a primary mechanism of weight loss.

What she gets wrong, or at least dramatically oversimplifies, is causality and safety framing. Stacking peptides without medical supervision is not a trivial choice. Combining compounds with overlapping mechanisms can amplify adverse effects including severe nausea, vomiting, hypoglycemia risk, and cardiovascular stress. She presents a personal anecdote about a specific dose as though it is informative guidance, which it is not. One person's response to an unverified compound at an unverified dose tells you nothing about what another person should do. The "way too much" admission actually implies she experienced something uncomfortable, though she does not elaborate on what that was.

What should you actually know?

Retatrutide is not FDA-approved. It is an investigational compound with promising early trial data, but it is not available through standard pharmacy channels. If someone is using it, they are almost certainly using a compounded version, which is not equivalent to a clinical trial formulation. Compounded drugs are not FDA-approved and have not been evaluated for safety and efficacy in the same way.

Peptide stacking, combining two or more GLP-1 class or related agents at the same time, has no established safety or dosing protocol outside of controlled research settings. The "no food noise" experience she describes may be real, but it could also reflect early adverse effects being misread as positive ones. Anyone considering retatrutide or any compounded peptide should be working with a licensed clinician, not calibrating doses based on social media content. Nguyen et al. (2023, Obesity Reviews) noted that off-label and compounded GLP-1 use is outpacing the clinical evidence base significantly.